AbbVie Inc. (ABBV) stock
Close on Nov 11, 2026Market cap $521.26BP/E 83.3Yield 2.25%
AbbVie Inc. grew revenue 10.4% to $64.39B over the twelve months to Jun 30, 2026. Operating income rose 53.8% to $16.87B, moving the operating margin from 18.8% to 26.2%. Free cash flow was $18.21B, down 0.2% from a year earlier. At the latest close the market valued the company at $521.26B, 83.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $521.26B
- P/E ratio
- 83.3
- Price to sales
- 8.10
- Price to book
- –
- Dividend yield
- 2.25%
- Free cash flow yield
- 3.49%
Fundamentals
- Revenue
- $64.39B
- Net income
- $6.31B
- EPS, diluted
- $3.54
- Free cash flow
- $18.21B
- Book value per share
- -$3.35
- Diluted shares
- 1.77B
Trading
- Next earnings
- Feb 3, 2027 (estimated, before the open)
- Previous close
- $293.89
- Open
- $291.36
- Day's range
- $289.73 – $295.46
- Volume
- 3,262,250
- Average volume (20 days)
- 5,419,236
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.28
- 52-week range
- $190.75 – $302.93
- RSI (14 days)
- 62.8
- Volatility (1 year)
- 25.6%
- Relative volume
- 0.64×
- WACC
- 6.9%
On 1 of our idea list: Superinvestor favorites
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABBV | S&P 500 | Difference | ABBV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.4% | -2.4% | +9.8 pts | ||
| 3 months | +18.7% | -1.2% | +19.8 pts | ||
| Year to date | +33.0% | +12.3% | +20.7 pts | ||
| 1 year | +34.9% | +12.4% | +22.5 pts | ||
| 3 years | +135.2% | +78.8% | +56.4 pts | +33.0% | +21.4% |
| 5 years | +202.1% | +75.2% | +126.9 pts | +24.7% | +11.9% |
| 10 years | +602.6% | +311.1% | +291.5 pts | +21.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AbbVie filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About AbbVie
Pharmaceutical Preparations
AbbVie is a biopharmaceutical company that discovers, develops, manufactures, and sells medicines and therapies. The company operates through a single global business segment covering therapeutic areas such as immunology, oncology, neuroscience, aesthetics, and eye care. Its key products include immunology medications such as Skyrizi, Rinvoq, and Humira; neuroscience therapies like Vraylar and Botox Therapeutic; oncology treatments including Imbruvica and Venclexta; and aesthetic offerings such as Botox Cosmetic and Juvederm fillers. AbbVie markets its products to physicians, healthcare providers, managed care organizations, hospitals, government agencies, and consumers. Its customers also include wholesale distributors, independent retailers, and specialty pharmacies.
Company profile, executives and historyAbbVie stock: common questions
What is AbbVie's stock price?
ABBV closed at $294.98 on Nov 11, 2026, up 0.37% on the day. Over the past 52 weeks it traded between $190.75 and $302.93.
What is AbbVie's market cap?
AbbVie was worth $521.26B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ABBV's P/E ratio?
ABBV trades at 83.3 times earnings, based on diluted earnings per share of $3.54 over the twelve months to Jun 30, 2026.
How much revenue does AbbVie make?
AbbVie reported revenue of $64.39B for the twelve months to Jun 30, 2026, up 10.4% from a year earlier.
Does AbbVie pay a dividend?
Yes. AbbVie paid $6.65 per share over the last twelve months, a yield of 2.25% at the latest price, and has raised its annual dividend 11 years in a row.
When does AbbVie report earnings next?
AbbVie is expected to report Q4 FY2026 results on Feb 3, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ABBV stock performed over the past year?
Including dividends, ABBV returned +34.9% over the past year, against +12.4% for the S&P 500.
How many ABBV shares are sold short?
16M shares were sold short at the latest FINRA report, 0.90% of the float, or 3.3 days of average trading volume.
Who are AbbVie's competitors?
Companies most similar to AbbVie by business, industry and size include BMY, LLY, PFE, ABT, MRK.
See a number that looks wrong?